We recently compiled a list of the 8 Best Immunology Stocks to Buy According to Hedge Funds. Eli Lilly and Company (NYSE:LLY) is among the best immunology stocks.
TheFly reported on May 26 that LLY agreed to acquire Vaccine Company, Inc., a clinical-stage biotech focused on in vivo nanoparticle vaccine technology designed to mimic virus-like particle immune responses without the complex manufacturing required for traditional VLP approaches. The company’s pipeline includes multiple preclinical programs targeting viral diseases, with its lead Epstein-Barr Virus candidate advancing toward Phase 1 readiness using a five-antigen design.
The acquisition deal values Vaccine Company at up to $1.55 billion in cash, structured with an upfront payment plus additional milestone-based payouts tied to clinical and commercial progress. The technology is being explored for the prevention of EBV-related conditions, including infectious mononucleosis and potential long-term neurological and oncologic outcomes.
Separately, on May 25, Eli Lilly and Company (NYSE:LLY) reported positive Phase 1b Heart-2 study data for VERVE-102, an investigational in vivo base-editing therapy intended to permanently inactivate the PCSK9 gene in the liver to reduce LDL cholesterol after a single infusion. The study enrolled adults with heterozygous familial hypercholesterolemia or premature coronary artery disease.
Interim results from 35 participants showed a single intravenous dose produced dose-dependent declines in circulating PCSK9 protein ranging from 51% to 88%, alongside LDL-C reductions spanning 9% to 62% across dose groups. These lipid-lowering effects were sustained, with durability observed for up to 18 months after treatment, supporting prolonged therapeutic activity following one administration.
Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical company focused on developing treatments in cardiometabolic diseases, oncology, immunology, and neuroscience. It is a growing leader in immunology, with a portfolio of biologic and targeted therapies for immune-mediated inflammatory conditions.
While we acknowledge the risk and potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 12 Best Strong Buy Tech Stocks to Invest In Now and 10 Most Widely Held Stocks by Individuals in 2026 .
Disclosure: None. Follow Insider Monkey on Google News.
